ALB and non-small cell lung carcinoma: In a retrospective study, Fiala et al. (28) analyzed 457 patients with advanced NSCLC receiving erlotinib treatment and found that pretreatment Alb levels were independent predictors of both progression-free survival (PFS) and overall survival (OS).